BIGG

Resultados: 8

Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)

NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....

Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)

NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....

Problema de Salud AUGE N°84: Mieloma Múltiple en personas de 15 años y más
Health Problem AUGE N°84: Multiple Myeloma in people 15 years and older

El Mieloma Múltiple es un tipo de neoplasia hematológica maligna incurable en la actualidad, que se caracteriza por la afección y multiplicación sin control de células plasmáticas en la médula ósea con su consecuente secreción de una proteína monoclonal y síntomas como anemia, hipercalcemia, f...

Myeloma: diagnosis and management

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications....

Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients

Med. clín. (Barc); 147 (5), 2016
"BACKGROUND AND OBJECTIVE: Poor mobilization of peripheral blood stem cells (CD34(+) cells) from bone marrow is a frequent reason for not reaching the autologous stem cell trasplantation (SCT) procedure in patients diagnosed with lymphoma or myeloma. Plerixafor, a reversible inhibitor of the binding of s...

Myeloma: diagnosis and management

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications....

Myeloma: diagnosis and management - update information

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications. This guideline...

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

Ann. hematol; 91 (6), 2012
In this project, we produced drug-specific recommendations targeting the use of new agents for multiple myeloma (MM). We used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system which separates the judgments on quality of evidence from the judgment about strength of recom...